ADVFN ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

APTA Aptamer Group Plc

0.38
0.00 (0.00%)
Share Name Share Symbol Market Type Share ISIN Share Description
Aptamer Group Plc LSE:APTA London Ordinary Share GB00BNRRP542 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.38 0.36 0.40 0.3965 0.38 0.38 32,152,698 08:00:25
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 860k -2.96M -0.0015 -2.53 7.3M
Aptamer Group Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker APTA. The last closing price for Aptamer was 0.38p. Over the last year, Aptamer shares have traded in a share price range of 0.205p to 0.70p.

Aptamer currently has 1,920,000,000 shares in issue. The market capitalisation of Aptamer is £7.30 million. Aptamer has a price to earnings ratio (PE ratio) of -2.53.

Aptamer Share Discussion Threads

Showing 6226 to 6249 of 6575 messages
Chat Pages: Latest  251  250  249  248  247  246  245  244  243  242  241  240  Older
DateSubjectAuthorDiscuss
16/5/2025
05:05:41
TRUSTWORTHY CRYPTOCURRENCY RECOVERY SPECIALIST AROUND //HIRE META TECH RECOVERY PRO

Ask (META TECH RECOVERY PRO) for help via:
Telegram:@metatechrecoveryproteam
W/S +1 (469) 692‑8049

I would not wish the circumstances I recently endured upon anyone. The experience, spanning several months, resembled a tumultuous journey of constructing an ephemeral dream, and I had nearly resigned and accepted the permanent loss of my crypto digital assets. I incurred substantial financial losses due to a lack of information on the cryptocurrency investment scheme. After acknowledging these losses, I sought assistance from numerous self-proclaimed recovery specialists, each promising aid, only to ultimately be disappointed. Following months of fruitless endeavors, I discovered META TECH RECOVERY PRO. Despite my skepticism, driven by desperation, my initial outreach marked the beginning of an extraordinary experience. From the very start, their unique qualities shone through. They were professional with me and exceptionally responsive. They avoided making baseless claims, choosing instead to explain their approach, set realistic goals, and immediately begin their work. Their team, comprised of cyber forensics and blockchain experts with years of experience and successful records of digital assets claim back. Thoroughly investigated every facet of my transactions, tracking wallet addresses, pinpointing unusual activities, and uncovering hidden routes to my missing funds. Within days, significant advancements were visible. They successfully retrieved my lost digital assets, a feat that had proven impossible for others. META TECH RECOVERY PRO's integrity and its focus on achieving results were truly remarkable. They not only returned my assets but also restored my faith in digital asset recovery. because honestly, at some point, I thought recovering lost digital assets was a fairy tale. If you are facing a similar challenge, bypass the delays I endured; instead, engage with the experts who produce a certified outcome for your task. META TECH RECOVERY PRO converted my financial losses into a breakthrough by successfully recovering not only my invested funds but also my profits.
Thank you.

mateolucas11211
15/5/2025
22:30:58
So four licensing deals aligned all 10%[and these last ones with milestone payments too . Cash runway June next year and royalties will kick in by then too . No cash raise coming here just patience required . Directors can't buy shares while in talks otherwise I reckon they would be buying .

More FFS work to come soon imo and the big ones like Unilever and AZ still to come too .

Sooner this seller goes the better as this should be a lot higher on those royalty deals alone

Then there is this snippet

Aptamer's ongoing collaboration with AstraZeneca continues to generate compelling data, and multiple pharmaceutical companies have initiated discussions to explore partnerships over the next few months."

bones698
15/5/2025
17:32:03
Timbo, there is a bull flag on APTA.


Not confirmed yet.

May or may not be a holder.


SSB
BWTFDIK

sideshowbull
15/5/2025
16:41:02
Could be nico115?
walter walcarpets
15/5/2025
16:24:48
Hi Multi

"could be some parties to the 0.20p raise last year are banking profits and recouping capital"

Given the size of the raise, I think thats a good hunch.

Would be interesting to add up the entire volume traded since the fundraising and the size of the fundraising and compare them.

Adam

adamb1978
15/5/2025
16:04:35
Reality is you dont know the conversion timings or pipeline additions as of today ... ;-)
squire007
15/5/2025
13:49:39
“Such contracts can sometimes take extended periods to negotiate with its lengthening list of customers, primarily because Aptamer insists on securing the best contractual terms and conditions to ensure all agreements capture the best long-term growth potential and prospective licensing returns.”

They do have such a good sense of humour! Nothing to do with customers not being ready to sign then….

The reality is…
8/7/24 RNS
“These efforts have led to increased revenues in the second half of the year and an encouraging rise in order book values. In the last quarter of the financial year, £0.98 million in orders were won which has resulted in a total of £1.8 million in signed orders currently being processed or awaiting processing in the laboratory.”

Even when the contracts are signed the £1.8m only turned into £700k in six months to 31/12/24 snd another £500k to 30/6/25.

purchaseatthetop
15/5/2025
12:00:39
Nobody gives a toss what you think
dplewis1
15/5/2025
11:26:20
Bones. APTA will already be arranging the cash raise. IIs can sell now knowing they can recover the shares at a lower price later. That’s what I think.
purchaseatthetop
15/5/2025
11:19:05
There is an ii selling that is surpressing the price they have been selling for months and caused the fall back to 0.22p . They now seem happy to sell around this level . Not sure how many they have left but once cleared this will take off imo. Judging by the amount they have sold in the last few months it must be coming to an end pretty soon hopefully.

Seen this happen with other shares once they are cleared we will see quite big gains imo,good time to be buying as it's just a case of when

bones698
15/5/2025
11:03:40
New research note from Turner Pope:
timbo003
15/5/2025
10:38:50
The "market" seems to unable to recognise this....or it could be some parties to the 0.20p raise last year are banking profits and recouping capital ?

The latter is my gut feeling and a TR1 could come out, if regulations are adhered to, but there is plenty wriggle room.

Gives another opportunity to add :)

multibagger
15/5/2025
10:18:01
Quoted spread (.34/.40) 16% diabolical - However most trades within the spread and it is only a sub 1p stock so I suppose justified.
pugugly
15/5/2025
10:12:43
Fantastic news and the market still doesn't acknowledge the success . Just wait one day this will take off when it finally sinks in
bones698
15/5/2025
09:02:18
All fish in the sea are not the same !!! Fekk sound like Cantona.. back to bed :-))
squire007
15/5/2025
08:59:37
Also have a look at POLX, AGL, STX etc etc who all had gamechanging amazing certain to be successful IP……R30;.
purchaseatthetop
15/5/2025
08:56:04
The scientific implications of being able to target multi-organ, fibrotic pathology is a real game changer in being able to get a precise radar "lock on" to targets of interest, hitherto inaccessible and in areas of high unmet medical need. Potential for offshoots of this to find its way into veterinary applications at a lower price point.

The RNS then goes on to state that they have been able to deliver 3 types of SiRNA payloads - which can be likened to "munitions" .....this could be a huge step towards the holy grail of being able to reverse fibrosis.

Make no mistake - this is scientifically massive and commercially a goldmine as once this technology is incorporated into pharma regulatory filings for progression of research, it becomes a golden goose for milestone payments and royalties close to perpetuity.

The other facet is that this tech can be "salami sliced" for each fibrotic organ application..... this tech alone will make APTA a very attractive takeover target.

Watch this space or better still, be a part of this incredible journey unfolding !

multibagger
15/5/2025
08:51:52
Parsons. If the tech snd skills are do great and commercially needed by mega pharmas, how come revenue for six months to 31/12/24 was £700k and is forecast to be £500k max in next six months to 30/6/25? That seems like revenue is falling not growing.
purchaseatthetop
15/5/2025
08:48:17
Someuwin

Adam Hargreaves was previously with Astra Zeneca for a substantial period of time obviously his contacts are still in place there and it's off shoots now occurring

gepetto100
15/5/2025
08:40:31
Its a 2year hold for me... 1st in class so bide your time
squire007
15/5/2025
08:39:24
Another great RNS, yes they are making great progress, but may still need further financing. I don't think raising additional capital will be a problem because it is now when and not if they become profitable.
parsons4
15/5/2025
08:31:57
Adam Hargreaves @adshargreaves ·9m

We can now target any systemic (e.g lung, liver, kidney), or local (e.g. dermal/ophthalmologic) fibrotic disease, with very first-in-class genetic knockdown therapy opportunities. We have great data and we have great interest. #AIM #APTA

someuwin
15/5/2025
08:26:12
Great to see this is in addition to those reported at interim results - another royalties being negotiated

Arron Tolley
We are pleased to report the additional licensing opportunity, which has been identified and agreed upon since the interim results and has demonstrated the dedication of our commercial team. We are committed to negotiating the best terms available for the Group and have now delivered three double-digit licensing agreements this year.

gepetto100
15/5/2025
08:18:39
Last final accounts:

“At the end of September 2024, we have signed deals progressing through the laboratory giving a current total of £0.9 million of revenue visibility this financial year. This value is subject to scientific attrition, with our average realisation being approximately 60-70% of the maximum.”

That is why £231k is really £160k. Glad to help. By all means listen to the to the moon believers but some balance is also needed. Good luck.

purchaseatthetop
Chat Pages: Latest  251  250  249  248  247  246  245  244  243  242  241  240  Older

Top Brokers in the UK

Spread Bet
CFD
Forex
Share

Your Recent History

Delayed Upgrade Clock